责任医疗组织对前列腺癌诊断检测的影响
本研究基于Medicare数据,回顾性分析2011至2014年无前列腺癌男性的PSA检测与前列腺活检率,比较ACO与非ACO医生患者。结果显示PSA检测率总体下降22.3%,活检率下降7.0%;ACO参与未差异影响PSA检测下降,但ACO医生患者活检率上升。
要点
- 2011至2014年,无前列腺癌男性PSA检测率下降22.3%,活检率下降7.0%。
核心结论
- ACO参与未加速PSA检测的减少,但ACO医生患者的前列腺活检率有所增加。
主要发现
- 2011至2014年,PSA检测率从618降至530/1000人(ACO医生患者),从607降至516/1000人(非ACO医生患者),总体下降22.3%。
- 前列腺活检率总体下降7.0%;非ACO医生患者活检率保持12/1000人,ACO医生患者从11.6升至12.5/1000人。
临床怎么用
- ACO参与未加速PSA检测的降级实施,临床决策应结合患者具体情况。
- ACO医生患者活检率上升,需关注活检指征的合理性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine if Accountable Care Organizations (ACOs) have the potential to accelerate the impact of prostate cancer screening recommendations. METHODS: We performed a retrospective cohort study using Medicare data evaluating the rates of PSA testing and prostate biopsy among men without prostate cancer between 2011 and 2014. We assessed PSA testing and biopsy rates before and after policy implementation among patients of ACO and non-ACO-aligned physicians. To control for secular trends, difference-in-differences methods were used to determine the effects of ACO implementation. RESULTS: We identified 1.1 million eligible men without prostate cancer. From 2011 to 2014, the rates of PSA testing and biopsy declined by 22.3% and 7.0%, respectively. PSA testing declined similarly regardless of ACO participation-from 618 to 530 tests per 1000 beneficiaries among ACO-aligned physicians and from 607 to 516 tests per 1000 beneficiaries among non-ACO-aligned physicians (difference-in-differences P = .11). Whereas rates of prostate biopsy remained constant for patients of non-ACO-aligned physicians at 12 biopsies per 1000 beneficiaries, these rates increased from 11.6 to 12.5 biopsies per 1000 beneficiaries of patients of ACO-aligned physicians (difference-in-differences P = .03). CONCLUSION: PSA testing and prostate biopsy rates decreased significantly between 2011 and 2014. The rate of PSA testing was not differentially affected by ACO participation. Conversely, there was an increase in the rate of prostate biopsy among patients of ACO-aligned physicians. ACOs did not accelerate deimplementation of PSA testing for eligible Medicare beneficiaries without prostate cancer.
引用
- Luckenbaugh AN, Hollenbeck BK, Kaufman SR, et al. Impact of Accountable Care Organizations on Diagnostic Testing for Prostate Cancer. Urology. 2018. PMID: 29630957. doi:10.1016/j.urology.2018.01.056
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。